Five subjects ( &data_1_%; ) &row_1_1; due to a TEAE.----Discontinued from treatment|Adverse event||16 mg/kg||5 (4.7%)----Five subjects (5%) discontinued from treatment due to a TEAE.
Eleven &row_1_1; ( &data_1_%; ) had &row_1_1;----Subjects with major protocol deviation||Total||11 (8.9%)----Eleven subjects (9%) had major protocol deviations.
Seven ( &data_1_%; ) &row_1_1; &row_1_2; &row_1_1; study &row_1_2; &row_1_1; inclusion/exclusion &row_1_2; ( see brief narratives below ) .----Subjects with major protocol deviation|Entered but did not satisfy criteria||Total||7 (5.6%)----Seven (6%) subjects entered the study but did not satisfy the inclusion/exclusion criteria (see brief narratives below).
Three &row_1_1; ( &data_1_%; ) &row_1_2;----Subjects with major protocol deviation|Received wrong treatment or incorrect dose||Total||3 (2.4%)----Three subjects (2%) received wrong treatment.
One &row_1_1; in &row_1_1; &column_1_1; group was considered to have had a &row_1_1; captured as &row_1_2; &row_1_1; not having an ECG completed at screening.----Subjects with major protocol deviation|Other*||16 mg/kg||1 (0.9%)----One subject, in the 16 mg/kg group was considered to have had a major protocol deviation captured as “other” for not having an ECG completed at screening.
The &row_1_2; &row_1_1; received was &data_1_Float; &row_1_1; ( 1 &row_1_1; = 28 days ) .----Number of treatment cycles|Median||16 mg/kg||4.0----The median number of treatment cycles received was 4.0 cycles (1 cycle = 28 days).
Forty subjects ( &data_1_%; ) received &row_1_2; &row_1_1; daratumumab &row_1_1;----Number of treatment cycles|At least 6 cycles||16 mg/kg||40 (37.7%)----Forty subjects (38%) received at least 6 cycles of daratumumab treatment.
For all treated subjects, the &row_1_2; &row_1_1; was 100% of the target &row_1_1; for both treatment groups ( 8 and 16 mg/kg ) .----Relative dose intensity (%)|Median||Total||100.01----For all treated subjects, the median relative dose intensity was 100% of the target dose for both treatment groups (8 and 16 mg/kg).
In the &column_1_1; group, at the time &row_1_2; the primary analysis, &data_1_%; &row_1_2; subjects had PFS &row_1_2; ( progressed &row_1_2; died ) , based &row_1_2; IRC assessment ( Table 6 ) .----Progression-free survival|Number of events (%)||16 mg/kg||75 (70.8%)----In the 16 mg/kg group, at the time of the primary analysis, 71% of subjects had PFS events (progressed or died), based on IRC assessment (Table 6).
At the time of the primary analysis, the &row_1_2; PFS ( &row_1_1; ) was 3.7 &row_1_1; ( &row_1_2; 2.8, 4.6 ) .----Kaplan-Meier estimate (months)|Median (95% CI)||16 mg/kg||3.65 (2.76, 4.63)----At the time of the primary analysis, the median PFS (Kaplan-Meier estimate) was 3.7 months (95% CI: 2.8, 4.6).
The &row_1_1; PFS &row_1_1; was 37% ( &row_1_1; 27%, 46% ) .----6-month progression free survival rate % (95% CI)||16 mg/kg||36.7 (27.0, 46.4)----The 6-month PFS rate was 37% (95% CI: 27%, 46%).
The &row_1_1; PFS &row_1_1; was 18% ( &row_1_1; 11%, 28% ) &row_1_1; &column_1_1; group.----12-month progression free survival rate % (95% CI)||16 mg/kg||18.3 (10.7, 27.5)----The 12-month PFS rate was 18% (95% CI: 11%, 28%) for the 16 mg/kg group.
In the &column_1_1; group, &data_1_%; &row_1_1; subjects had experienced &row_1_1; the &row_1_1; the primary analysis.----Time to disease progression|Number of events (%)||16 mg/kg||73 (68.9%)----In the 16 mg/kg group, 69% of subjects had experienced disease progression at the time of the primary analysis.
The &row_1_2; time to progression was 3.7?months.----Kaplan-Meier estimate (months)|Median (95% CI)||16 mg/kg||3.71 (2.79, 5.39)----The median time to progression was 3.7?months.
&row_1_1; overview of &row_1_1; by treatment received during the study is presented in Table 1.All but 1 subject had 1 or more reported &row_1_1; ( &data_1_%; ) .----Any TEAE||Total||123 (99.2%)----An overview of TEAEs by treatment received during the study is presented in Table 1.All but 1 subject had 1 or more reported TEAE (99%).
